Ads
related to: glaxo smith kline website storeeuautomation.com has been visited by 100K+ users in the past month
temu.com has been visited by 1M+ users in the past month
Search results
Results from the WOW.Com Content Network
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4] [5] The company's product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas such as anti-infectives, dermatology, gynaecology, diabetes, oncology ...
Rotarix (human rotavirus vaccine, live attenuated) Shingrix (for Zoster Vaccine Recombinant, Adjuvanted) Synflorix (pneumococcal polysaccharide conjugate vaccine (adsorbed)) Twinrix (for combined hepatitis A (inactivated virus) and hepatitis B vaccine (genetically derived surface antigen)) Typherix (typhoid vaccine (purified polysaccharide ...
Glaxo (GSK) has made significant progress in its pipeline. Several new drug/line extension approvals are expected in 2021/2022, which should boost the top line in the long term
Smith, Kline & French (SKF) was an American pharmaceutical company. History. In 1830, John K. Smith opened a drugstore in Philadelphia, and his younger brother, George, joined him in 1841 to form John K Smith & Co. In 1865, Mahlon Kline joined the company, as a bookkeeper. In 1875, he took on additional responsibilities as a salesman and added ...
Glaxo invests heavily in R&D, in order to bring to market new drugs and treatments that it can sell to health care providers and patients around the world. In 2011, for instance, R&D investment ...
LONDON -- The FTSE 100 set a five-and-a-half-year record of 6,638 points last Friday, and though the index is down from that today at 6,617, it still looks like hanging on to the 6,600 level ...
Dame Emma Natasha Walmsley DBE (born June 1969) is the chief executive officer (CEO) of GlaxoSmithKline. [1] She succeeded Sir Andrew Witty, who retired in March 2017. [2] Before GSK, she worked for L'Oréal for 17 years, and was a non-executive director of Diageo until September 2016. [3] She grew up in Barrow-in-Furness, Cumbria, England.
Ads
related to: glaxo smith kline website storeeuautomation.com has been visited by 100K+ users in the past month
temu.com has been visited by 1M+ users in the past month